Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice
Molecular Pharmaceutics · 2023
DOI: 10.1021/acs.molpharmaceut.3c00715 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Myriam El Biali und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Medical University of Vienna, 1090 Vienna, Austria. Hauptthemen laut MEDLINE: ATP Binding Cassette Transporter, Subfamily B, Member 1, Breast Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Austrian Science Fund FWF, Austrian Science Fund.
Abstract (Originalsprache)
P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) are two ATP-binding cassette efflux transporters that are coexpressed at the human blood-brain barrier (BBB) and blood-retina barrier (BRB). While pharmacological inhibition of P-gp and/or BCRP results in increased brain distribution of dual P-gp/BCRP substrate drugs, such as the tyrosine kinase inhibitor erlotinib, the effect of P-gp and/or BCRP inhibition on the retinal distribution of such drugs has hardly been investigated. In this study, we used positron emission tomography (PET) imaging to assess the effect of transporter inhibition on the distribution of [11C]erlotinib to the human retina and brain. Twenty two healthy volunteers underwent two PET scans after intravenous (i.v.) injection of a microdose (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Medical University of Vienna, 1090 Vienna, Austria.
- Inserm UMRS1144, Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Cité, F-75006 Paris, France.
- Service Pharmacie, Assistance Publique-Hôpitaux de Paris, Hôpital Universitaire-Necker-Enfants Malades, F-75015 Paris, France.
- Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, 1090 Vienna, Austria.
- Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), CEA, CNRS, Inserm, Service Hospitalier Frédéric Joliot, Université Paris-Saclay, 91401 Orsay, France.
ORCID-Profile: Oliver Langer
Förderung
- Austrian Science Fund FWF
- Austrian Science Fund
Zitieren
APA
Biali, M. E., Auvity, S., Cisternino, S., Smirnova, M., Hacker, M., Zeitlinger, M., Mairinger, S., Tournier, N., Bauer, M., & Langer, O. (2023). Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00715
Vancouver
Biali ME, Auvity S, Cisternino S, Smirnova M, Hacker M, Zeitlinger M, et al. Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.3c00715
BibTeX
@article{Biali2023,
author = {Biali, Myriam El and Auvity, Sylvain and Cisternino, Salvatore and Smirnova, Maria and Hacker, Marcus and Zeitlinger, Markus and Mairinger, Severin and Tournier, Nicolas and Bauer, Martin and Langer, Oliver},
title = {Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice},
journal = {Molecular Pharmaceutics},
year = {2023},
doi = {10.1021/acs.molpharmaceut.3c00715}
}
EUVIMED